A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Clinical trial NCT07287098 · RECRUITING

Trial details

NCT number: NCT07287098
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2026-05-13
Primary completion: 2029-01-01
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.